KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Other Non Operating Income (2016 - 2025)

Pfizer (PFE) has disclosed Other Non Operating Income for 17 consecutive years, with -$4.5 billion as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income changed N/A to -$4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.7 billion through Dec 2025, changed N/A year-over-year, with the annual reading at -$6.7 billion for FY2025, 53.24% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$4.5 billion at Pfizer, down from -$517.0 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $1.7 billion in Q4 2021, with the low at -$4.5 billion in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$352.6 million, with a median of -$275.0 million recorded in 2023.
  • The sharpest move saw Other Non Operating Income surged 628.42% in 2021, then tumbled 1576.0% in 2024.
  • Over 5 years, Other Non Operating Income stood at $1.7 billion in 2021, then plummeted by 96.52% to $59.0 million in 2022, then surged by 169.49% to $159.0 million in 2023, then plummeted by 252.83% to -$243.0 million in 2024, then crashed by 1757.61% to -$4.5 billion in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$4.5 billion, -$517.0 million, and -$739.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.